Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gossamer Bio (GOSS) EBITDA Margin (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of EBITDA Margin data on record, last reported at 362.87% in Q3 2025.

  • For Q3 2025, EBITDA Margin fell 1987.0% year-over-year to 362.87%; the TTM value through Sep 2025 reached 587.03%, down 51248.0%, while the annual FY2024 figure was 60.63%, N/A changed from the prior year.
  • EBITDA Margin reached 362.87% in Q3 2025 per GOSS's latest filing, up from 370.24% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1710.33% in Q3 2022 and bottomed at 390.85% in Q1 2025.
  • Average EBITDA Margin over 4 years is 684.07%, with a median of 795.74% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: plummeted -154386bps in 2024, then plummeted -1987bps in 2025.
  • A 4-year view of EBITDA Margin shows it stood at 1612.76% in 2022, then fell by -26bps to 1200.87% in 2023, then tumbled by -67bps to 390.62% in 2024, then crashed by -193bps to 362.87% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 362.87% in Q3 2025, 370.24% in Q2 2025, and 390.85% in Q1 2025.